FDG-PET in monitoring therapy of breast cancer
FDG-PET in monitoring therapy of breast cancer
复制标题
DOI：
10.1007/s00259-004-1533-x
复制
发表时间：
2004-06-01
影响因子：
9.1
通讯作者：
Palmedo, H
中科院分区：
文献类型：
--
作者：
Biersack, HJ;Bender, H;Palmedo, H
氟-18氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）已成功地用于乳腺癌的分期和再分期。另一个重要指标是治疗反应的评价。关于乳腺癌放射治疗后使用FDG-PET的数据有限。化疗也是如此。只有局部晚期乳腺癌化疗后的治疗反应已被彻底研究。在第一和第二疗程后，可预测组织学反应，准确率为88-91%。当FDG-PET用于治疗监测时，定量评估当然是先决条件。只有少数研究关注激素治疗。在这种情况下，已经观察到在开始他莫昔芬治疗后标准化摄取值增加的耀斑现象。需要更多的前瞻性多中心试验，使FDG-PET成为监测乳腺癌化疗的有力工具。
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88-91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer.